Wedbush bullish on Maze Therapeutics, initiates with an Outperform

As previously reported, Wedbush analyst Laura Chico initiated coverage of Maze Therapeutics (MAZE) with an Outperform rating and $17 price target The firm sees the Maze development strategy as promising both in terms of its target identification strategy and application to the nephrology/metabolic disease segments. Both the MZE829 and MZE728 programs also incorporate an element of derisking with external competitors already providing target validation evidence, Wedbush says. Combining multiple near-term catalysts with cash runway into the second half of 2027, and the firm sees favorable risk/reward for Maze’s shares as the stock trades near a $500M valuation.